Julius Clinical to coordinate worldwide study on the effects of alcohol

The health effects of moderate (no more than 2 alcoholic beverages each day) alcohol consumption is still debated. Many studies have found that adults who reported drinking alcohol in moderation tended to develop heart disease and diabetes less often than adults who drank no alcohol. However, other studies found opposite results or showed no relationship between alcohol intake and these diseases. This study hopes to definitively answer this question.

read more

Meet us at these upcoming events

We will be attending several conferences in the coming months and we would enjoy the opportunity to speak with you at them. If you are interested in finding out how we can help you run a cost-effective and creative trial, send us an email. We look forward to seeing you.

American College of Cardiology in Orlando, Florida: 10-12 March

BioEurope Spring in Amsterdam, The Netherlands: 12-14 March

World Vaccine Conferencein Washington, DC: 3-5 April

read more

EU H2020 grant for unique HIT-Cystic Fibrosis project

The EU has granted 6.7 M€ from the Horizon 2020 research program to a broad collaborative group of researchers, doctors, pharmaceutical companies and patient representatives. Julius Clinical is one of the consortium partners and will be responsible for global Site Management, Monitoring, Data Management and Safety Management for the clinical part of the project. For more details, please click here

read more

A successful and valuable RSV Vaccines for the World Conference

The annual RSV Vaccines for the World Conference was held this year in Malaga Spain, from Nov 29th to Dec 1st. The conference was organised by ReSViNET, the RSV network managed and operated by Julius Clinical and the University Medical Center Utrecht.

read more

Jennifer Hart joins Julius Clinical

We are pleased to announce that Jennifer Hart has joined our company as Executive Director Business Development North America. In her new role as Executive Director, Ms. Hart will oversee the North American Business Development efforts for Julius Clinical and Cohortias, a joint venture between Julius Clinical and Zumanis. 

read more

Amsterdam is the new home for the European Medicines Agency

Amsterdam has succeeded in its bid to host the European Medicines Agency (EMA) when the organisation leaves London following Brexit.

read more

Andrew Copestake joins Julius Clinical

Julius Clinical is proud to announce that Andrew Copestake has been appointed as our new Chief Business Development Officer starting immediately. He will be part of the Management team together with Messrs. Smink (CEO), Grobbee (CSO) and Van Dijk (COO).

read more

Julius Clinical Forms Alliance With Parexel

Alliance aims to strengthen global clinical trial services by aligning scientific and operational aspects of clinical trials

Utrecht, Netherlands, January 25, 2017 — Julius Clinical, a globally-operating Academic Research Organization (ARO), today announced it has entered into a non-exclusive alliance with PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation. The alliance provides biopharmaceutical companies an approach to aligning scientific and operational aspects of a clinical trial.

read more